-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

Benzinga·03/18/2025 16:58:29
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and maintains $35 price target.